Los Angeles and San Diego, CA, May 12, 2021 – Expansion a key part of its growth strategy to help transform patient care.
ImaginAb Inc, a leading biotechnology company focused on developing next generation imaging and therapeutic radiopharmaceuticals (RPT), and headquartered in Los Angeles, today announced the incorporation of ImaginAb Europe, Ltd based in Bracknell, United Kingdom and formation of a European based team.
As part of the Company’s growth strategy an initial European team has been established, consisting of Dr. Gareth Smith, PhD as General Manager – Europe., and Dr. Michael Ferris, PhD as Project Associate.
The team will lead the expansion of ImaginAb operations into Europe developing and building new commercial partnerships and collaborations with European based pharmaceutical and biotech businesses. Dr Smith, and his team will leverage their industrial radiopharmaceutical experience to work closely with ImaginAb’s existing pharma and clinical research partners to improve its CD8 Immuno-PET supply chain. His role will also entail portfolio management of activities regarding radiopharmaceutical therapy agent (RPT) development.
On his appointment Gareth Smith said, “I am very excited to join such an innovative company in the radiopharmaceuticals arena at a time when its products are gaining wider acceptance and being incorporated into many upcoming clinical trials of both big pharma and biotech companies. I look forward to working as part of such a great team and driving the expansion of ImaginAb operations and R&D activities with respect to CD8 ImmunoPET and new RPT development.”
Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb added:
“Over the last 2 years we have seen a substantial increase in both our early-stage R&D programs and clinical programs, with clinical studies in the US, Europe and Australia.
Building a European presence and team, under the leadership of Gareth, will allow us to accelerate our growth plans, work more closely with our R&D and commercial partners and help us to realise our aim to transform patient care.
Gareth, has over 12 years’ extensive experience in the development and commercialization of imaging and therapeutic radiopharmaceuticals, and is well placed to support our current and future plans.”
ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineer antibody fragments called Minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET Imaging technology and therapeutic isotopes, these novel Minibodies bind specifically to cell surface targets, providing physicians with a whole-body picture of immune activity and the potential to treat cancer.
ImaginAb is advancing a pipeline of Minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma.
For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.
About CD8 ImmunoPET
The 89Zr CD8 Immuno-PET agent ([89Zr]-Df-IAB22M2C) is a [89Zr]-labeled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.
For further information please contact:
Phone: +1 310 645 1211
General Manager – Europe
Phone: +44 (0) 1344 390 536